Manufacturers seeking to market medical devices in the Czech Republic in 2026 must comply with EU Medical Device Regulation (EU MDR 2017/745), including EUDAMED registration, as well as oversight by the State Institute for Drug Control (SÚKL). The Czech Republic continues to maintain a transparent regulatory system that aligns closely with EU standards while ensuring patient safety and market integrity.
Manufacturers seeking to place medical devices on the Czech market in 2026 must comply with EU MDR (Regulation (EU) 2017/745) and IVDR (Regulation (EU) 2017/746), alongside national requirements under Act No. 375/2022 Coll. on Medical Devices and In Vitro Diagnostic Medical Devices; the Czech implementing legislation that has been legally binding since May 26, 2021. The State Institute for Drug Control (SÚKL) serves as the national competent authority and enforces both EU-level and Czech-specific requirements.
2026 marks a pivotal compliance year: manufacturers, authorized representatives, and importers must provide actor and device data to EUDAMED before placing any device on the Czech or EU market, in compliance with Article 31 MDR/IVDR and from May 28, 2026, this obligation is fully mandatory. Simultaneously, Czech-specific registry obligations through ISZP remain active for distributors and service providers. Understanding both the EU-level and national-level requirements is essential for seamless Czech market access.
Regulatory Authority in the Czech Republic
The primary regulatory body is SÚKL (Státní ústav pro kontrolu léčiv).
SÚKL is responsible for:
- Registration and approval of medical devices
- Market surveillance and inspections
- Field Safety Corrective Actions and vigilance monitoring
- Oversight of clinical investigations and conformity assessments
- Supervision of distributors, importers, and manufacturers operating in the country
SÚKL ensures all medical devices marketed in the Czech Republic meet EU MDR requirements and harmonized European standards.
SÚKL (Státní ústav pro kontrolu léčiv) is the primary regulatory body responsible for registration and approval of medical devices, market surveillance and inspections, Field Safety Corrective Actions and vigilance monitoring, oversight of clinical investigations and conformity assessments, and supervision of distributors, importers, and manufacturers operating in the country.
A significant 2025 development: the Czech Metrology Institute was formally established as a new notified body for medical devices in the Czech Republic. This is a meaningful addition to the Czech regulatory infrastructure: the Czech Metrology Institute joins the existing designated notified bodies serving the Czech and broader EU market. Manufacturers seeking conformity assessment services with Czech-based notified bodies now have an additional option, which may be relevant for capacity planning given the well-documented EU-wide notified body obstacle.
Device Classification
The Czech Republic follows the EU MDR risk-based classification system:
- Class I: low-risk devices
- Class IIa: low-to-medium risk
- Class IIb: medium-to-high risk
- Class III: high-risk devices
Devices are also categorized by type, including general medical devices, in vitro diagnostics (IVDs), and active implantable devices. Manufacturers classify their devices according to EU MDR Annex VIII rules. Class I devices can be self-certified by the manufacturer, while Class IIa, IIb, and III devices require Notified Body involvement for conformity assessment. Combination products are classified according to their primary intended purpose.
The Czech Republic follows the EU MDR four-class risk-based classification system: Class I (low risk), Class IIa (low-to-medium risk), Class IIb (medium-to-high risk), and Class III (high risk). IVDs are classified under IVDR into Class A (lowest risk) through Class D (highest risk).
Manufacturers classify their devices according to EU MDR Annex VIII rules. Class I devices can be self-certified by the manufacturer, while Class IIa, IIb, and III devices require notified body involvement.
An important practical note: many devices previously classified at lower risk under the MDD have been reclassified to higher risk classes under MDR: particularly software, substance-based devices, and reusable surgical instruments. Manufacturers should verify their current MDR classification before initiating any Czech registration process, as misclassification causes downstream delays in conformity assessment and SÚKL review.
CE Marking and Conformity Assessment
To place a device on the Czech market:
- All devices must carry a CE marking indicating MDR compliance
- Class I devices follow simplified conformity procedures and can be self-certified
- Class IIa, IIb, and III devices require Notified Body involvement for conformity assessment
- Documentation supporting compliance must be retained for at least five years (ten years for implantable devices)
- All labeling and instructions must be in Czech language, including country of origin, product details, warnings, and instructions for use
- Compliance with harmonized European or international standards (such as ISO 13485, ISO 14971) is mandatory
Class I device registration typically takes 4-6 weeks following submission to SÚKL.
All devices placed on the Czech market must carry CE marking indicating MDR or IVDR compliance. Class I devices follow simplified conformity procedures and can be self-certified; Class IIa, IIb, and III devices require notified body involvement. Documentation supporting compliance must be retained for at least five years (ten years for implantable devices).
Czech-language labeling is a firm national requirement. All labeling and instructions for use must be in the Czech language, including country of origin, product details, warnings, and instructions for use. This is a common source of delay for international manufacturers; Czech-language labeling preparation should be treated as a parallel work stream to technical documentation, not a final step.
Compliance with harmonized European and international standards, including ISO 13485 (quality management systems), ISO 14971 (risk management), and applicable IEC/ISO performance standards, is expected. Class I device registration with SÚKL typically takes 4–6 weeks following submission, assuming documentation is complete.
EUDAMED Registration and Authorized Representatives
From May 28, 2026, EUDAMED registration is mandatory for all medical devices in the EU, including the Czech market. Manufacturers, authorized representatives, and importers must provide actor and device data to EUDAMED before placing any device on the market, in compliance with Article 31 MDR/IVDR.
Key EUDAMED deadlines:
- May 28, 2026: All new devices must be registered in EUDAMED before being placed on the EU/Czech market
- November 27, 2026: Legacy devices already on the market before May 28, 2026 but continuing to be sold must be registered in EUDAMED’s UDI/Device module
- All economic operators (manufacturers, authorized representatives, importers) must obtain a Single Registration Number (SRN) through the Actor module before placing devices on the market
The four mandatory EUDAMED modules from May 28, 2026 are: Actor Registration, UDI/Device Registration, Notified Bodies and Certificates, and Market Surveillance. The Vigilance and Clinical Investigations modules will become mandatory at a later date.
Non-EU manufacturers must appoint an EU Authorized Representative, who bears legal compliance responsibility under MDR/IVDR and serves as the SÚKL’s primary point of contact. The manufacturer, authorized representative and importer shall provide actor and device data to EUDAMED before placing the device on the market.
Supply Interruption Notifications: As of January 2025, Regulation (EU) 2024/1860 requires manufacturers to notify competent authorities of any supply interruptions or discontinuations that could result in serious harm to patients; a proactive obligation that did not exist under the previous framework.
Supply Interruption Notifications:
As of January 2025, Regulation (EU) 2024/1860 requires manufacturers to notify authorities of any supply interruptions or discontinuations that could result in serious harm to patients.
Czech Device Registries: RZPRO & ISZP
- ISZP (Medical Devices Information System) is the current system for distributors and service providers to notify their operations and submit device information. Data from the previous RZPRO system has been migrated to ISZP.
- RZPRO (Register of Medical Devices) continues to be used provisionally for certain transitional activities, including tracking Field Safety Notices and registered entities, pending full EUDAMED implementation.
Distributors, persons servicing medical devices, and manufacturers of custom-made medical devices are obliged to notify SÚKL via the Medical Device Information System (ISZP) before commencing their operations, in accordance with Sections 8 and 23 of the Act on Medical Devices.
Important exceptions: This obligation does not apply to a distributor who supplies exclusively Class I medical devices or Class A IVD medical devices, or who supplies devices exclusively to a user who is not a healthcare provider. Nor is it mandatory for a person servicing exclusively Class I medical devices or Class A IVD medical devices.
When notifying an operation to ISZP, the submission must include a list of medical devices being supplied, with each device’s name, intended purpose, risk class, and basic UDI-DI (if assigned). The notified person is obliged to confirm the accuracy of the notified data within one year of the date of notification. SÚKL will make the confirmation function available in ISZP 60 days before the expiry of this one-year period.
If an entity does not confirm the validity of data within 30 days of notification, the notified activity will be invalidated and an entity without a valid activity in ISZP cannot perform distribution or service activities.
Regarding RZPRO: RZPRO continues to be used provisionally for clinical investigation applications and notifications under Article 62, Article 74(1) and (2) of EU Regulation 2017/745, requests for substantial changes, and reporting of serious adverse events from clinical investigations until the Clinical Investigations Module in EUDAMED is fully operational. Clinical investigations pursuant to Article 82 MDR are notified via ISZP.
Czech Medical Device Market Overview
The Czech Republic is a promising market for both domestic and international manufacturers:
- Population: ~10.6 million
- High demand for advanced diagnostics and home care devices
- Popular products include high-end ultrasounds, video endoscopes, and home care equipment
- Strong regulatory transparency encourages innovation while ensuring patient safety
- Growing market with increasing healthcare investment
Manufacturers should align Czech market entry with EU-wide MDR compliance for efficient multi-country access.
The Czech Republic is a strategically attractive market for both domestic and international manufacturers. With a population of approximately 10.6 million, the Czech healthcare system features high demand for advanced diagnostics, surgical equipment, and home care devices. Popular product categories include high-end ultrasounds, video endoscopes, and home care equipment.
The Czech Republic’s position as a central European manufacturing and logistics hub adds strategic value beyond its domestic market. As a full EU member state, CE-marked devices registered in the Czech Republic have access to the entire EU single market making Czech market entry an efficient gateway for broader European expansion. Czech regulatory transparency and SÚKL’s active engagement with EU regulatory developments make it a predictable and manageable market for international manufacturers compared to some other EU jurisdictions.
Key Takeaways for 2026
To commercialize medical devices in the Czech Republic in 2026:
- Ensure full compliance with EU MDR 2017/745 and Act No. 375/2022 Coll.
- Obtain valid CE marking through the appropriate conformity assessment route, verify your MDR classification before initiating conformity assessment.
- Complete EUDAMED registration by the mandatory deadlines: May 28, 2026 for new devices; November 27, 2026 for legacy devices.
- Appoint an EU Authorized Representative if you are a non-EU manufacturer and ensure AR-manufacturer EUDAMED linking is completed.
- Follow Czech registry obligations via ISZP: distributors and service providers above the Class I/A threshold must notify before commencing operations.
- Ensure all labeling and IFU are in Czech language, prepare translations in parallel with technical documentation.
- Maintain structured post-market surveillance and vigilance systems.
- Notify authorities of supply interruptions per Regulation (EU) 2024/1860.
- Implement ISO 13485 QMS. Consider the Czech Metrology Institute as an option for Czech-based notified body services for conformity assessment.
Conclusion
The Czech Republic offers a transparent, predictable regulatory environment for medical device manufacturers but 2026 brings an elevated compliance burden with EUDAMED’s mandatory rollout, active ISZP notification obligations, and Czech-specific labeling requirements all running in parallel. Manufacturers who treat EUDAMED registration, Czech-language labeling, and ISZP notification as integrated work streams rather than sequential tasks will be best positioned to achieve smooth Czech market access and maintain compliance throughout the product lifecycle.
Navigating the dual-track EUDAMED and SÚKL/ISZP compliance requirements, Czech-language labeling obligations, and EU MDR/IVDR technical documentation standards requires up-to-date regulatory intelligence and a structured market entry strategy. RegDesk’s AI-powered RIMS monitors SÚKL guidance updates, EUDAMED deadlines, and EU MDR/IVDR developments across the Czech Republic and 120+ global markets helping medical device manufacturers stay ahead of registration requirements, manage technical documentation, and coordinate multi-country EU submissions from a single platform. Whether you are entering the Czech market for the first time or managing ongoing compliance, RegDesk gives your regulatory team the clarity and confidence to move forward.
FAQ
Q: Do I need to register with both EUDAMED and SÚKL/ISZP in the Czech Republic?
A: It depends on your role. Manufacturers, authorized representatives, and importers must register in EUDAMED and provide actor and device data before placing devices on the Czech/EU market. Distributors, persons servicing medical devices, and manufacturers of custom-made devices must notify SÚKL via the ISZP system before commencing operations in the Czech Republic. The two systems serve different functions and are not interchangeable; EUDAMED is the EU-level device registration database, while ISZP is the Czech national notification system for local economic operators.
Q: Is EUDAMED registration now mandatory for the Czech market and what are the deadlines?
A: Yes. From May 28, 2026, the four mandatory EUDAMED modules are legally required. New devices must be registered in EUDAMED before the first unit is placed on the Czech or EU market. Legacy devices already on the market before May 28, 2026 but continuing to be sold must be registered by November 27, 2026. All economic operators must hold a valid Single Registration Number (SRN) obtained through EUDAMED’s Actor module before these deadlines.
Q: Are there any exemptions from ISZP notification for distributors in the Czech Republic?
A: Yes, the ISZP notification obligation does not apply to a distributor who supplies exclusively Class I medical devices or Class A IVD medical devices, or who supplies devices exclusively to a user who is not a healthcare provider. It also does not apply to persons servicing exclusively Class I medical devices or Class A IVD medical devices. Distributors and service providers above these thresholds must notify SÚKL via ISZP before commencing operations and must confirm the accuracy of their notified data annually.
Q: What happens if I don’t confirm my ISZP data on time?
A: If an entity does not confirm the validity of the data within 30 days of SÚKL’s notification prompt, the notified activity will be invalidated. An entity without a valid activity in ISZP cannot perform distribution or service activities effectively blocking legal operations in the Czech Republic until the issue is resolved. SÚKL makes the confirmation function available 60 days before the one-year anniversary of notification, giving entities a clear window to act.
Q: Is Czech-language labeling mandatory and when should I prepare it?
A: Yes, all labeling and instructions for use must be in the Czech language, including country of origin, product details, warnings, and instructions for use. This is a national requirement under Act No. 375/2022 Coll. Czech-language labeling should be prepared in parallel with technical documentation; not treated as a final step. Late-stage translation is one of the most common causes of Czech market entry delays for international manufacturers, and mislabeled products may be subject to SÚKL enforcement action.
